Table 2.
Summary of cases who took an extend course of Paxlovid outside the context of an acute re-infection and did not experience any improvement
| Case # | Age, gender | Date of COVID infection(s) | Likely variant | Initiation of Long COVID symptoms | COVID vaccinations | Date and length of extended course of Paxlovid | Short-term improvement with Paxlovid | Sustained improvement with Paxlovid | Adverse effects of Paxlovid |
|---|---|---|---|---|---|---|---|---|---|
| 8 | 35 y.o. woman | July 2020 | original wild type | Jul 2020 | 2021 (Apr, May, Nov), 2022 (Jun, Oct) | Apr 2023 (10 d) | |||
| 9 | 34 y.o. woman | Nov 2021 | delta | Nov 2021 | 2021 (Oct, Nov) | May 2022 (15 d) | |||
| 10 | 45 y.o. woman | Jan 2022 | omicron | Jan 2022 | 2021 (May, July), 2022 (Jan, Sept) | Nov 2022 (15 d) | |||
| 11 | 37 y.o. woman | March 2020 | original wild type | Mar 2020 | 2021 (Apr, Nov), 2022 (Nov) | Feb 2023 (15 d attempted) | y |